was observed. In addition, a significant increase in muscle strength and a reduction in body fat could be demonstrated.

**Conclusion** Due to the initial significantly reduced cardiorespiratory fitness of the patients, but with promising first data showing a benefit of the patients after the training program, a follow-up study with a larger SLE patient collective over a period of 2 years is planned. In addition, a murine comparative study will be initiated in the spontaneous lupus mouse model of the MRL-Fas lpr mice. On the one hand, the influence of physical exercise on disease activity and progression of SLE should be analysed. Furthermore, we want to investigate the effects of physical activity on the musculature (inflammation, necrosis and fibrosis) and cardiovascular damage.

---

**P126 TOLERABILITY, EFFICACY AND ADHERENCE: WHAT DO LUPUS PATIENTS THINK ABOUT TREATMENT?**


10.1136/lupus-2020-eurolupus.170

**Background** The treatment of systemic lupus erythematosus (SLE) can be challenging due to the complex nature of symptoms, yet despite recent advances in treatment, patients’ opinion and medication beliefs are poorly understood. Furthermore, patient understanding of treatment plays a major role in medication adherence. In this study we aimed to understand patient experiences relating to treatment.

**Methods** Thirteen patients attended a patient engagement event. They were asked to answer 12 structured treatment-based questions designed to assess medication beliefs. Round table discussions were held where patients shared their experiences to allow for both qualitative and quantitative data collection.

**Results** The majority of patients (74.5%) believed that they had a good understanding of their current treatment with many accessing medication-related information through consultation with their rheumatologist or specialist nurse (93.3%), via patient information sheets (33%) and by using online resources (46.6%).

Many patients (76.9%) reported that they had concerns before starting a new treatment, in particular in relation to potential side effects and ultimate treatment duration. A substantial number (75%) of patients reported a previous adverse reaction or side effect to treatment. Just over half of participants (54.6%) were previously advised by their doctor to stop taking a medication because it was not effective. Interestingly, 40% said they had stopped taking their medication on their own accord, usually due to side effects, with 54.5% reported stopping treatment due to feeling it to be ineffective.

**Conclusions** In summary this work shows that patients are concerned about adverse events associated with treatment and supports new research to identify ways to mitigate those effects.

---

**P127 LONG-TERM EFFECTS OF COMBINED B-CELL IMMUNOMODULATION WITH RITUXIMAB AND BELIMUMAB IN SEVERE, REFRACTORY SLE: TWO YEAR RESULTS RITUXIMAB AND BELIMUMAB COMBINATION FOR SEVERE SLE**

1Tineke Kraaij, 1Eline J Arends, 1Laura S van Dam, 1Sylvia WA Kamerling, 2Paul LA van Daele, 2Obbo W Bredewold, 2Angho Ray, 2Jaap A Bakker, 2Hans U Scherer, 3Tom JW Huizinga, 3Ton J Rabelink, 3Cees van Kooten, 3YK Onno Teng. 1Dept of Nephrology, LUMC, Leiden; 2Dept of Clinical Immunology, Erasmus MC, Rotterdam; 3Dept of Clinical Chemistry and Laboratory Medicine, LUMC, Leiden; 4Dept of Rheumatology, LUMC, Leiden, The Netherlands

10.1136/lupus-2020-eurolupus.171

**Background** Anti-CD20 B-cell depletion has not shown superior efficacy to standard immunosuppression in patients with systemic lupus erythematosus (SLE). Besides trial design,